Introduction to Medical Pharmacology
Module 6 — Rational Prescribing and Drug Information
Chapter 1 · Module 6 of 6Section 1
A structured approach to drug selection, dosing, and monitoring that applies pharmacological principles to individual patient care
Rational prescribing is the disciplined application of pharmacological knowledge to patient care. It is the clinical translation of everything covered in this chapter: understanding what a drug does, how the body handles it, who the patient is, and what the evidence says about the drug’s benefit-to-harm ratio in this specific situation. The framework for doing this is consistent across all drug classes and all clinical settings.
Rational prescribing requires explicit decisions about five things for every drug prescribed. The right drug means choosing based on evidence of efficacy for the specific indication, not habit, familiarity, or marketing. Drugs should be selected from those for which good evidence exists and for which the benefit-to-harm ratio is favorable for this patient’s condition.
The right dose means individualizing based on the patient’s pharmacokinetics — body weight, renal function, hepatic function, age, and relevant genetic factors — rather than applying a universal standard. Population-average doses are starting points, not endpoints.
The right route follows from the clinical urgency, the drug’s oral bioavailability, and the patient’s ability to take oral medication. Intravenous for emergencies and drugs with poor oral bioavailability; oral for chronic therapy when the patient can absorb reliably.
The right duration means prescribing for as long as the drug’s benefit continues to outweigh its risks, and no longer. Open-ended prescriptions without a defined therapeutic endpoint are a major source of unnecessary drug exposure and cumulative harm.
The right patient means explicitly reviewing contraindications, checking for drug-disease interactions, assessing all other medications for drug-drug interactions, and confirming that the patient understands and can adhere to the regimen. A drug that is appropriate for the indication but contraindicated in this specific patient is not a rational prescription.
When a drug has a long half-life and time to steady state that would require days to weeks of dosing, a loading dose — a larger initial dose — can be given to rapidly bring plasma concentrations into the therapeutic range. The maintenance dose, given at regular intervals thereafter, replaces the drug eliminated between doses and keeps concentrations within the therapeutic range at steady state. Digoxin, amiodarone, and some antiepileptics are common examples where loading doses are used clinically. The concept matters for understanding why a drug may not produce its full therapeutic effect immediately after starting, and why doubling the first dose is sometimes deliberately appropriate rather than an error.
Therapeutic drug monitoring is the measurement of plasma drug concentrations to guide dosing decisions. It is indicated for drugs where the relationship between plasma concentration and therapeutic or toxic effect is well-established, the therapeutic window is narrow, and significant interpatient pharmacokinetic variability exists that cannot be predicted from clinical parameters alone. Aminoglycoside antibiotics, vancomycin, digoxin, lithium, phenytoin, cyclosporine, and tacrolimus are the drug classes where therapeutic drug monitoring is most consistently used. The goal is to confirm that concentrations fall within the target range — high enough to be effective, low enough to avoid toxicity — and to adjust the dose when they do not.
Element 1
Right Drug
Element 2
Right Dose
Element 3
Right Route
Elements 4 & 5
Right Duration & Patient
Section 2
How drug exposure affects the developing fetus, the principles that guide prescribing decisions in pregnancy, and drug transfer into breast milk
Prescribing during pregnancy presents a unique pharmacological challenge because every drug decision involves two patients: the pregnant person and the developing fetus. The fetus lacks the physiological mechanisms to metabolize and eliminate drugs efficiently, and during critical windows of development, drug exposure can cause structural malformations, organ dysfunction, or growth restriction that would not occur at the same exposure in an adult.
A teratogen is any agent that causes structural or functional abnormalities in a developing organism. Drug teratogenicity is time-dependent: the developmental stage at which exposure occurs largely determines the type and severity of harm. The period of organogenesis — roughly weeks three through eight of gestation — is when developing organ systems are most vulnerable to structural malformation, because this is when the heart, limbs, brain, and other structures are forming their basic architecture. Exposure before implantation tends to produce an all-or-nothing effect (either the embryo is unaffected or fails to implant). Exposure during the fetal period after organogenesis is complete tends to affect organ growth, maturation, and function rather than gross structure.
Many drugs cross the placenta readily, particularly lipophilic drugs of low molecular weight. The fetal circulation concentrates some drugs at higher levels than in the maternal circulation. The fetal liver and kidneys are immature, so drugs that the mother would metabolize and eliminate rapidly may accumulate in the fetus to potentially harmful concentrations.
A core set of drug teratogens must be known by every prescriber. These are drugs where the teratogenic risk is well-established, clinically significant, and directly relevant to prescribing decisions in women of reproductive age.
| Drug or Class | Primary Fetal Risk | Clinical Implication |
|---|---|---|
| Isotretinoin (oral) | Severe craniofacial, cardiac, and central nervous system malformations; spontaneous abortion | Absolutely contraindicated in pregnancy. Mandatory pregnancy prevention program (iPLEDGE) required in the United States. |
| Warfarin | Warfarin embryopathy (nasal hypoplasia, bone stippling) in first trimester; fetal bleeding later | Switch to heparin (which does not cross the placenta) during pregnancy for anticoagulation. |
| Valproic acid | Neural tube defects, cognitive impairment, autism spectrum disorder | Avoid in pregnancy when possible. If required, folic acid supplementation and monitoring. Highest-risk antiepileptic. |
| Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers | Fetal renal dysgenesis, oligohydramnios, skull hypoplasia (second and third trimester) | Contraindicated in pregnancy. Switch to methyldopa, labetalol, or nifedipine for hypertension management. |
| Methotrexate | Fetal death, growth restriction, central nervous system and limb malformations | Contraindicated. Used as abortifacient at higher doses. Requires washout period before conception. |
| Thalidomide | Limb reduction defects (phocomelia), cardiac and gastrointestinal malformations | Strictly contraindicated. Historical cause of the major drug safety reform that established modern pre-approval testing requirements. |
| Tetracyclines | Discoloration and dysplasia of fetal teeth and bones | Avoid after week 14 of gestation. Safe alternatives exist for most bacterial infections. |
Most drugs transfer into breast milk to some degree. The clinical significance of this transfer depends on the amount of drug that reaches the infant, the infant’s ability to absorb, metabolize, and eliminate it, and the infant’s sensitivity to the drug’s pharmacological effects. The relative infant dose — the fraction of the maternal weight-adjusted dose that the infant receives through breast milk — is the primary measure used to assess lactation safety. A relative infant dose below 10 percent is generally considered acceptable for most drugs.
Drugs that are poorly absorbed orally, highly protein-bound, or of high molecular weight transfer poorly into milk or are poorly absorbed by the infant from milk. Lithium, certain antiepileptics, and some cytotoxic chemotherapy agents are examples of drugs where breastfeeding is generally contraindicated. Lactation-specific drug databases, particularly LactMed maintained by the National Institutes of Health, provide current evidence-based guidance that should be consulted before advising a breastfeeding patient about any specific drug.
The FDA Pregnancy Labeling Change
The FDA replaced its previous A/B/C/D/X pregnancy category system in 2015 with a narrative labeling format that provides detailed summaries of available human and animal data, clinical considerations, and risk estimates for each drug. The old letter categories were widely criticized for oversimplifying complex data and for being misinterpreted as a simple safety ranking. The new format requires prescribers to engage with the actual evidence rather than rely on a letter grade. For clinical practice and for Step 1, knowing which drugs are definitively teratogenic and why is more useful than memorizing the old category assignments.
Section 3
How to find reliable drug information, how to interpret clinical trial results, and how to recognize when published data are presented misleadingly
Prescribing is a continuous evidence-appraisal activity. New drugs enter the market, evidence for established drugs evolves, and the quality of information presented to prescribers ranges from rigorous and unbiased to selective and misleading. The ability to navigate drug information sources and interpret clinical trial statistics is as essential to safe prescribing as knowledge of pharmacology itself.
A drug reduces the rate of myocardial infarction from 4 percent in the placebo group to 2 percent in the treated group. The relative risk reduction is 50 percent: treatment halved the event rate. The absolute risk reduction is 2 percent: treatment prevented 2 events per 100 patients treated. The number needed to treat — the reciprocal of the absolute risk reduction — is 50: 50 patients must be treated to prevent one event.
The same data. Very different impressions. A 50 percent relative risk reduction sounds compelling. A number needed to treat of 50 — meaning 49 out of 50 patients receive no benefit while all 50 are exposed to the drug’s adverse effects and cost — provides a more complete picture. Pharmaceutical marketing consistently emphasizes relative risk reduction because the numbers are larger. Clinical decision-making requires the absolute risk reduction and number needed to treat. The baseline event rate in the untreated population determines how large the absolute benefit can be: the same relative risk reduction produces a much smaller absolute benefit when baseline event rates are low.
The Three Numbers That Matter in a Drug Trial
Absolute risk reduction = event rate in control group minus event rate in treatment group. This is the actual probability of benefit for a patient like those in the trial. Number needed to treat = 1 divided by the absolute risk reduction. This tells you how many patients must be treated for one to benefit. Relative risk reduction = absolute risk reduction divided by the control event rate. This is what pharmaceutical marketing uses. Always ask for the absolute risk reduction and number needed to treat before accepting a relative risk reduction as evidence of clinical meaningfulness.
Not all drug evidence carries equal weight. The hierarchy of evidence ranks study designs by their ability to minimize bias and confounding. At the top are systematic reviews and meta-analyses of randomized controlled trials, which synthesize the best available evidence across multiple trials. Individual well-conducted randomized controlled trials sit below these but above all observational designs. Cohort studies and case-control studies can identify associations but cannot establish causation with the same confidence as a randomized controlled trial. Case series and expert opinion occupy the bottom of the hierarchy and are the least reliable basis for prescribing decisions, though they may be all that is available for rare conditions or special populations excluded from trials.
Clinical practice guidelines are developed by expert panels that apply this hierarchy to make recommendations. The GRADE system (Grading of Recommendations Assessment, Development and Evaluation) provides a transparent framework for rating the quality of evidence and the strength of recommendations based on that evidence. A strong recommendation based on high-quality evidence carries very different meaning from a strong recommendation based only on expert consensus from cohort data.
Drug information sources exist on a spectrum from primary literature to tertiary references. Primary sources are original peer-reviewed research: randomized controlled trials, systematic reviews, and pharmacokinetic studies published in indexed medical journals. These require critical appraisal skills to use effectively. Secondary sources synthesize primary literature: the Cochrane Database of Systematic Reviews and evidence-based clinical databases such as UpToDate and DynaMed provide clinician-directed summaries with explicit evidence grading. Tertiary sources such as standard pharmacology textbooks and prescribing references provide general background but may lag current evidence.
For specific prescribing information, the FDA-approved prescribing information (package insert or label) is the authoritative source for approved indications, contraindications, dosing, and safety data as reviewed by the FDA. Drug interaction checkers, renal dosing calculators, and pregnancy and lactation databases (LactMed for lactation, MotherToBaby for pregnancy) are evidence-based tools that are appropriately integrated into clinical practice. Pharmaceutical company marketing materials, popular health websites, and social media are not appropriate primary sources for prescribing decisions.
Section 4
How drug errors occur, what system and individual factors contribute to them, and how a safety culture prevents harm
Medication errors are among the most common causes of preventable patient harm in healthcare. They occur at every stage of the medication use process: prescribing, transcription, dispensing, administration, and monitoring. Understanding how errors happen — and what makes them more or less likely — is as much a part of clinical pharmacology as understanding drug mechanisms.
Prescribing errors are the largest category and include errors of commission (writing the wrong drug, dose, or route) and errors of omission (failing to prescribe a drug that is clearly indicated, or failing to discontinue one that is causing harm). Dose errors are particularly common: errors in decimal place position, errors in weight-based calculations, and errors arising from unfamiliarity with the dosing units for a specific drug are all well-documented patterns. Transcription errors arise in the translation of a prescriber’s order into an administration record; electronic prescribing systems have substantially reduced but not eliminated this category. Dispensing errors occur in the pharmacy, administration errors at the point of patient care, and monitoring errors when the expected response to a drug or its potential toxicity is not tracked.
A separate and increasingly recognized category is look-alike, sound-alike drug errors: errors arising from the visual or phonetic similarity between different drug names. Hydroxyzine and hydralazine, vinblastine and vincristine, clonidine and Klonopin — each pair has been implicated in serious medication errors. This is a systems problem as much as an individual knowledge problem, addressed through changes in drug naming conventions, labeling design, and electronic prescribing alerts.
Most medication errors arise from a combination of individual and system factors rather than from a single cause. Individual factors include knowledge gaps, cognitive overload in high-acuity or high-volume settings, fatigue, and interruptions during the prescribing or administration process. System factors include poorly designed ordering interfaces, absence of clinical decision support, high rates of verbal or telephone orders, insufficient pharmacy review time, and inadequate staffing ratios. The same human being who makes an error in a poorly designed system may perform flawlessly in a well-designed one. This is why modern patient safety frameworks focus on system redesign rather than solely on individual accountability.
Electronic prescribing with integrated clinical decision support is the most effective single system intervention for reducing prescribing errors. Decision support that alerts prescribers to drug interactions, dosing errors in renal impairment, allergy conflicts, and pregnancy contraindications at the point of prescribing prevents errors before they reach the patient. Pharmacist review of orders provides a second independent check and catches errors that electronic systems miss. Unit-dose dispensing, barcode medication administration systems, and independent double-checks for high-risk medications such as anticoagulants and insulin add additional safeguards at the administration stage.
At the individual prescriber level, the most consistently effective habits are: never abbreviate drug names or doses in handwritten orders; always specify the complete route and frequency; double-check any dose that seems unusually high or low; verify weight-based calculations independently; confirm renal function before prescribing renally cleared drugs; and review the complete medication list for interactions before adding any new drug. These are not additional burdens on busy practice — they are the pharmacological habits that distinguish safe prescribers from dangerous ones.
Closing the Chapter: Pharmacology as a Continuous Practice
This chapter has covered the foundational concepts of pharmacology: what drugs are and where they come from, how the body handles them, how they produce their effects, how they can cause harm, why patients respond differently, and how rational prescribing applies all of this to individual patient care. These are not concepts to be learned once and filed away. They are frameworks to be applied actively every time a drug is prescribed, dispensed, or administered. The student who leaves this chapter with a genuine understanding of why drugs behave as they do — not just what they do — has the foundation for safe, effective, evidence-based prescribing throughout a clinical career.
| Author / Organization | Title | Source |
|---|---|---|
| World Health Organization | Guide to Good Prescribing: A Practical Manual | WHO, 1994 (WHO/DAP/94.11) |
| Brunton LL, Hilal-Dandan R, Knollmann BC, eds | Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edition | McGraw-Hill, 2018 |
| Myles PS, Gin T | Statistical methods for anaesthesia and intensive care (including absolute versus relative risk reduction) | Butterworth-Heinemann, 2001 |
| Briggs GG, Freeman RK, Towers CV, Forinash AB | Drugs in Pregnancy and Lactation, 11th edition | Lippincott Williams & Wilkins, 2017 |
| National Institutes of Health, National Library of Medicine | LactMed: Drugs and Lactation Database | nlm.nih.gov/medlineplus/druginfo/mommy |
| Waller DG, Sampson AP | Medical Pharmacology and Therapeutics, 5th edition | Elsevier, 2018 |